Dealmaker’s Diary: The Rare Disease Fighter Trading at Bargain Prices
This biotech generates positive cash flow while others burn money. At 25x forward earnings, you’re getting tomorrow’s genetic breakthroughs at a discount.
Buy This, Not That: A Tale of Two Balance Sheets
Two tech giants with ugly charts but very different futures…
Monday Takeaways: Markets at a Crossroads After Finding Support
Markets rally as Trump walks back tariff threats. Shah Gilani explains why crossing 5,700 matters and where hidden risks still lurk.
This Payments Processor Just Had an AI-Driven Breakout
This payments processor shows strong fundamentals with 12.5% CROCI, a P/E of 13.7x, and promising AI integration.
Buy This, Not That: The Oil Stock That’s About to Break Out
We pit two oil giants against each other… see which one has better technicals, higher profit margins, lower debt-to-equity ratio, and stronger recovery from recent lows.
Monday Takeaways: We’re in Correction Territory… Here’s What’s Coming Next
The S&P 500 dropped more than 10% from its peak in just 16 trading days. Shah reviews key support levels that could determine market direction.
Why My System Loves This Insurance Powerhouse
With near-zero volatility and strong CROCI of 11.7x, Marsh McLennan offers exceptional stability plus AI innovation even during market turbulence.
Buy This, Not That: The Truth About This 7.34% Dividend
This 7.34% dividend looks attractive but isn’t sustainable. There’s a better option for financial stability and semiconductor exposure without tariff concerns.
Monday Takeaways: Why You Should Embrace This Market Pullback
Trading through tough times with an analytical approach
Dealmaker’s Diary: Timing Matters for This Unusual Energy Play
This stock isn’t your typical energy play. Alpesh’s unusual timing strategy for this $3B natural gas provider helps dodge volatility while capturing upside.